AIM ImmunoTech, Inc.(NYSE Amex Equities : AIM)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||6.47%||11.85||0.7%||$828.36m|
|VRTX||Vertex Pharmaceuticals, Inc.||2.63%||192.46||1.9%||$541.53m|
|GILD||Gilead Sciences, Inc.||1.93%||67.94||1.0%||$485.03m|
|REGN||Regeneron Pharmaceuticals, Inc.||1.94%||540.06||2.7%||$393.60m|
|ALXN||Alexion Pharmaceuticals, Inc.||1.20%||181.99||2.0%||$335.71m|
|EXAS||EXACT Sciences Corp.||0.30%||131.37||18.1%||$176.59m|
|TXG||10X Genomics, Inc.||-1.67%||198.04||0.0%||$175.73m|
|BNGO||Bionano Genomics, Inc.||-0.15%||7.24||0.0%||$155.90m|
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.